Joel Solis, MD
Family Medicine · McAllen, TXNPI 1033191424
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $206,405 of the $323,715 with a category attached, or 63.8%. Amgen accounts for 74.0% of it on its own, with 59 other manufacturers making up the rest. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,683 payments — averaging $192.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$240K
- AstraZeneca$68K
- Novo Nordisk$3K
- AbbVie$2K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$971
- plus $9K from 54 others
Across 1,806 payments — averaging $11,513 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$11M
- AstraZeneca$3.5M
- Janssen Research & Development, LLC$1.4M
- Sanofi US Services Inc.$1.3M
- Boehringer Ingelheim International GmbH$1.3M
- AbbVie$1.2M
- plus $1.2M from 16 others
What the payments were for
- Consulting fees$32,14910%
- Speaking & faculty fees$206,40564%
- Travel & lodging$55,01817%
- Food & beverage$29,9749%
- Education$1690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$323,715 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $163,655 |
| MounjaroTirzepatide | 99 | $118,113 |
| FarxigaDapagliflozin Propanediol | 73 | $89,972 |
| JardianceEmpagliflozin | 82 | $80,955 |
| TrulicityDulaglutide | 52 | $73,591 |
| RybelsusSemaglutide | 40 | $62,986 |
| XareltoRivaroxaban | 28 | $36,873 |
| EliquisApixaban | 30 | $34,811 |
| Repatha SureclickEvolocumab | 22 | $26,588 |
| ProliaDenosumab | 16 | $26,272 |
| MyrbetriqMirabegron | 21 | $21,742 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $17,650 |
| GemtesaVibegron | 21 | $14,262 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $11,310 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $8,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,940 | $226,641159 claims |
| Lilly USA, LLCMounjaro, Trulicity | $971 | $191,705151 claims |
| AstraZenecaFarxiga | $67,517 | $89,97273 claims |
| Boehringer IngelheimJardiance | $1,413 | $80,95582 claims |
| Johnson & JohnsonXarelto | $285 | $36,87328 claims |
| PfizerEliquis, Paxlovid | $633 | $36,24041 claims |
| AmgenProlia | $239,611 | $26,27216 claims |
| Astellas Pharma US IncMyrbetriq | $267 | $21,74221 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $219 | $14,26221 claims |
| MerckJanumet | $342 | $8,76011 claims |
| AbbVieSynthroid | $2,114 | $3,81642 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in McAllen
- Enrique GriegoMcAllen$179K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.